Tagworks Pharmaceuticals has announced the start of a Phase 0/1 clinical trial for TGW211, a radioimmunoconjugate targeting HER2-positive tumors. This study marks a significant milestone for the company.

Tagworks Pharmaceuticals has secured regulatory approval to commence a clinical trial for TGW211, targeting HER2+ tumors using cutting-edge radio-immunotherapy.

Tagworks Pharmaceuticals has received authorization for its clinical Phase 0/1 study of TGW211, a radiopharmaceutical targeting HER2+ tumors. Initial patient data is anticipated in 2026.

Tagworks Pharmaceuticals has received approval for a Phase 0/1 clinical trial for TGW211, a radiopharmaceutical targeting HER2+ tumors, facilitating a new treatment approach.

Tagworks Pharmaceuticals has initiated a Phase 0/1 clinical trial for TGW211, a cutting-edge treatment targeting HER2-positive tumors, designed to revolutionize cancer therapy.

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks' proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination of...